View Older Stories View More Recent Stories

Apr 7, 2022 01:00AM Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
Apr 7, 2022 12:59AM Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Apr 4, 2022 05:51AM Regeneron (REGN) and Sanofi (SNY) Announces FDA Acceptance of Dupixent for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Apr 4, 2022 01:00AM Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
Mar 26, 2022 10:00AM Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Mar 26, 2022 09:59AM Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
Mar 16, 2022 06:30AM Seagen (SGEN) and Sanofi (SNY) Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
Mar 16, 2022 06:30AM Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
Mar 16, 2022 06:20AM Sanofi (SNY) and Seagen (SGEN) Collaborate to Develop and Commercialize Antibody-Drug Conjugates
Mar 16, 2022 06:18AM Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
Feb 26, 2022 12:05PM Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
Feb 26, 2022 12:04PM Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis
Feb 26, 2022 12:00PM Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Feb 18, 2022 05:31AM Regeneron (REGN) and Sanofi (SNY) Announce CUPID STUDY B of Dupixent (dupilumab) Did Not Show Statistical Significance
Feb 18, 2022 01:00AM Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Feb 10, 2022 01:00AM FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Jan 31, 2022 01:00AM CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
Jan 19, 2022 01:00AM Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Jan 7, 2022 06:02AM Exscientia plc (EXAI) and Sanofi (SNY) Announce Strategic Collaboration to Develop AI-Drive Pipeline of Precision-Engineered Medicines
Jan 7, 2022 01:00AM Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Dec 13, 2021 04:53AM Regeneron (REGN) and Sanofi (SNY) Present Positive Phase 3 Dupixent Data in Children
Dec 13, 2021 01:00AM Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session
Dec 8, 2021 05:30PM New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
Nov 18, 2021 01:30AM Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline
Oct 25, 2021 05:32AM Regeneron (REGN) and Sanofi (SNY) Report Second Dupixent Phase 3 Trial Achieves Primary Endpoints Demonstrating Significant Disease Improvements
Oct 25, 2021 01:00AM Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
Oct 22, 2021 01:00AM Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
Oct 20, 2021 05:30PM Regeneron (REGN) Announces FDA Expands Approval of Dupixent to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Oct 20, 2021 05:30PM FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
Sep 21, 2021 05:49AM Regeneron (REGN) and Sanofi (SNY) to Present New Dupixent® Data for Dermatitis in Children at WCPD and EADV
Sep 21, 2021 01:00AM New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
Sep 19, 2021 11:30AM ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
Aug 30, 2021 01:00AM Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in ch
Aug 5, 2021 06:00AM Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Jul 29, 2021 01:00AM Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients  
Jun 28, 2021 01:00AM Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
Jun 25, 2021 06:23AM Regeneron (REGN), Sanofi (SNY) Announce Libtayo Approved by European Commission as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Jun 25, 2021 01:15AM Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Jun 25, 2021 01:00AM Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
Jun 1, 2021 06:48AM Sanofi (SNY) and Merck's (MRK) first and only six-in-one pediatric combination vaccine now available in the United States
Jun 1, 2021 06:45AM Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States
May 17, 2021 10:01AM Regeneron (REGN), Sanofi (SNY) pivotal data at ATS 2021 show Dupixent significantly reduced asthma attacks and improved lung function in children
May 17, 2021 10:00AM Les données d’un essai pivot présentées au Congrès 2021 de l’ATS montrent que Dupixent® (dupilumab) réduit significativement les crises d’asthme chez l’enfant et améliore sa fonction re
Apr 19, 2021 05:36AM Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE
Mar 16, 2021 07:08AM Global Blood Therapeutics (GBT) Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A. (SNY)
Mar 15, 2021 06:15AM Regeneron (REGN) and Sanofi (SNY) Phase 3 Trial of Libtayo Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on OS
Mar 15, 2021 02:00AM Arrêt prématuré de l’essai de phase III consacré à Libtayo® (cémiplimab) en monothérapie dans le traitement du cancer du col de l’utérus en raison d'un résultat positif en matière
Mar 4, 2021 06:17AM Regeneron (REGN), Sanofi (SNY) announce FDA accepts Dupixent for review in children with moderate-to-severe asthma
Mar 4, 2021 01:00AM La FDA accepte d’examiner Dupixent® (dupilumab) dans le traitement de l’asthme modéré à sévère de l’enfant
Feb 22, 2021 01:00PM FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
View More Recent Stories View Older Stories